Evotec And Bayer Kidney Disease Collaboration Advances SEMA3A Monoclonal Antibody Program Into Phase 2 Clinical Development
Benzinga Newsdesk 11 months ago
News
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon first dosing of first study participant in early 2026
- Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome
- Milestone payment to Evotec expected upon first dosing of first study participant in early 2026